戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1                Acetone acts as a preliminary stabilizing agent.
2 -neuronal cells against taxol, a microtubule-stabilizing agent.
3  selection of a preparation with a different stabilizing agent.
4 ot extract was used as both the reducing and stabilizing agent.
5 rate were used as precursors and starch as a stabilizing agent.
6      plant extract as a natural reducing and stabilizing agent.
7 XP3 demethylation upon restimulation with no stabilizing agent.
8 ears in the presence of Taxol, a microtubule stabilizing agent.
9 ent, or paclitaxel (10 microM) a microtubule-stabilizing agent.
10 reased in the presence of either microtubule stabilizing agent.
11 nhanced compared to that in the absence of a stabilizing agent.
12 -thione (AGTT) was used both as reducing and stabilizing agent.
13 cal trials include cholesterol as a membrane stabilizing agent.
14 zes including 10, 20, and 40 nm with a fixed stabilizing agent.
15 g denatured bovine serum albumin (dBSA) as a stabilizing agent.
16 cells were resistant to taxol, a microtubule stabilizing agent.
17 techin gallate, and curcumin as reducing and stabilizing agents.
18 s are a novel class of nontaxane microtubule-stabilizing agents.
19 oped to evaluate the efficacy of nanocluster stabilizing agents.
20  combinations of the most commonly used mood-stabilizing agents.
21 nature, stability of CuO NPs and activity of stabilizing agents.
22  conventional mediator-targeting drugs or MC-stabilizing agents.
23  using Tridax procumbens as the reducing and stabilizing agents.
24 e overcome by applying eutectic solvents and stabilizing agents.
25 l this entropy-costly process using tailored stabilizing agents.
26 sion in patients receiving antimanic or mood stabilizing agents.
27  photochromic molecules acting as dispersion-stabilizing agents.
28 h doxantrazole or cromoglycate, which are MC stabilizing agents.
29 sufficient response to monotherapy with mood-stabilizing agents.
30 e (10) represents a new class of microtubule-stabilizing agents.
31  without the use of any external reducing or stabilizing agents.
32 ter exposure to DNA-damaging and microtubule-stabilizing agents.
33  for evaluating activity of putative disease stabilizing agents.
34 hypoxia-inducible factor 1alpha (HIF-1alpha) stabilizing agents.
35 e preincubated with or without a microtubule stabilizing agent, 100 microM Taxol, at 37 degrees C for
36 he results support the theory that effective stabilizing agents act by favoring the most compact stru
37 response rate for ixabepilone, a microtubule-stabilizing agent, administered intravenously daily for
38 ing agent, BSA can also function as a strong stabilizing agent against reaggregation of single-layer
39 n the presence of ethylenediamine (EDA) as a stabilizing agent and gold nanorods (Au NRs) at 300 degr
40 ct (+)-discodermolide (DDM) is a microtubule stabilizing agent and potent inducer of senescence.
41 ltitargeted prototypes with activities as MT-stabilizing agents and/or inhibitors of the cyclooxygena
42 in yeast and bacteria, indicate that protein stabilizing agents are effective in vivo for correcting
43 ed with microfilament-disrupting or filament-stabilizing agents at levels comparable to those in untr
44 kotriene receptor antagonist, or a mast cell stabilizing agent before exercise.
45 oes not induce significant desorption of the stabilizing agent, binding energies of benzene to gold a
46 tions that incorporate alpha-tocopherol as a stabilizing agent but there are few studies of the effec
47     These results indicate that not all mood-stabilizing agents but only those, which have anticonvul
48  drugs because they are powerful microtubule-stabilizing agents, but the complexity of their chemical
49 ls was facilitated by use of the protofibril-stabilizing agent calmidazolium chloride.
50 t mouse strains and mice treated with the MC stabilizing agent cromolyn sodium had dramatically reduc
51 (BL-3 cells) with the mitochondrial membrane-stabilizing agent cyclosporine (CSA) reduced LKT-mediate
52 Treatment of cells with taxol, a microtubule stabilizing agent, did not induce MEKK1 cleavage in cell
53 ained without the need for any surfactant or stabilizing agent, due to the strong electrostatic repul
54 extract has revealed as a very promising oil stabilizing agent during frying, playing an important ro
55 ctylbenzene molecules as graphene dispersion-stabilizing agents during the graphite LPE process.
56 ficance in that they allow the separation of stabilizing agent effects on nanocluster formation from
57 terventional study of the brain-penetrant MT-stabilizing agent, epothilone D (EpoD), in aged PS19 mic
58              We demonstrate here that the MT-stabilizing agent, epothilone D (EpoD), is brain-penetra
59 les were also incubated 1 h with microtubule stabilizing agents, epothilone D or discodermolide, foll
60  suitability of Chachafruto flour (CHF) as a stabilizing agent for an oil-in-water emulsion and its i
61 xtracts could serve as a color enhancing and stabilizing agent for anthocyanin colorants.
62 ptides were further used as the reducing and stabilizing agents for generation of peptide-bound AuNCs
63 ide, we examined combinations of microtubule-stabilizing agents for synergistic effects on tubulin as
64 proach using plant materials as reducing and stabilizing agents for the synthesis of important nanopa
65  Lithium is one of the most widely used mood-stabilizing agents for the treatment of bipolar disorder
66  with the Ag clusters and serve as effective stabilizing agents for these clusters.
67 elective synthesis of the potent microtubule-stabilizing agent FR182877 is described.
68 lpha in the cytoplasm, whereas a microtubule-stabilizing agent had no effect.
69         In contrast, treatment with an actin-stabilizing agent had no significant effect on NKCC1 pro
70                        As brain-penetrant MT-stabilizing agents have proven effective against tau-med
71 ins form a promising class of quadruplex DNA stabilizing agents having high selectivity for quadruple
72  subsample concomitantly treated with a mood-stabilizing agent (hazard rate ratio=1.16, 95% CI=0.63-2
73 and in the subsample not treated with a mood-stabilizing agent (hazard rate ratio=1.16, 95% CI=0.65-2
74 zation was blocked by the potent microtubule stabilizing agent hexylene glycol, but was unaffected by
75 d to assess the influence of the presence of stabilizing agents (HNO(3), Triton X-100 and ethanol) on
76                                       With a stabilizing agent (i.e., methylene blue and sodium phosp
77  different application platforms and how the stabilizing agents improve their plasmonic properties at
78 ation of polyvinyl chloride (PVC) waste as a stabilizing agent in proportions ranging from 2.5 to 30%
79 n by utilizing sulfur quantum dots (SQDs) as stabilizing agents in a Pickering emulsion.
80 ver nanoparticles (IY-AgNPs) as reducing and stabilizing agents in different conditions.
81 ne B, EPO906), a novel nontaxane microtubule stabilizing agent, in treatment of multiple myeloma (MM)
82                                  Microtubule-stabilizing agents including Taxol, epothilone B, and di
83 eatments, they are not well defined for mood-stabilizing agents, including lithium.
84                    Paclitaxel, a microtubule-stabilizing agent, induces a caspase-dependent apoptosis
85 import by low-dose paclitaxel, a microtubule-stabilizing agent, inhibits cholangiocarcinoma invasiven
86  by mixing different quantities of fruit and stabilizing agents (inulin, pectin and gellan gum), ther
87 ic agent paclitaxel (TaxolTM), a microtubule stabilizing agent, is known to arrest cells at the G2/M
88 he taccalonolides are a class of microtubule stabilizing agents isolated from plants of the genus Tac
89 lly and mechanistically distinct microtubule-stabilizing agents isolated from Tacca chantrieri.
90 lyphenols acting as the natural reducing and stabilizing agents leading to the formation of uniformly
91                                     The mood-stabilizing agents lithium and valproic acid (VPA) incre
92  a combination of endocrine therapy and DAXX-stabilizing agents may inhibit ER(+) tumor recurrence.
93 he combination of endocrine therapy and DAXX-stabilizing agents may inhibit tumor recurrence in ER(+)
94                                           MC-stabilizing agents, mediator-targeting drugs, and drugs
95 ults suggest that certain brain-penetrant MT-stabilizing agents might provide a viable therapeutic st
96 n cancer cell lines resistant to microtubule stabilizing agents (MSAs) and in human tumors resistant
97                                  Microtubule stabilizing agents (MSAs) comprise a class of drugs that
98                 A number of microtubule (MT)-stabilizing agents (MSAs) have demonstrated or predicted
99     One class of drugs, known as microtubule stabilizing agents (MSAs), binds to microtubule polymers
100                                  Microtubule-stabilizing agents (MTSAs), including the taxanes and ep
101 the DNA-damaging drug doxorubicin or the p53 stabilizing agent Nutlin-3, however, is accompanied by p
102                              The presence of stabilizing agents of QDs in the droplet was found to ca
103 ies were performed to examine the effects of stabilizing agents on the transport and retention of ful
104 is a potent, structurally unique microtubule-stabilizing agent originally isolated from the marine sp
105  enhanced in the presence of the microtubule-stabilizing agent paclitaxel (Taxol).
106 suppression of microtubule turnover with the stabilizing agent paclitaxel has no effect on BKV infect
107 in cells treated with either the microtubule-stabilizing agent paclitaxel, or an inactive form of col
108 ns, which did not occur with the microtubule-stabilizing agent paclitaxel.
109 treatment with a low dose of the microtubule-stabilizing agent paclitaxel.
110  SGNs were more sensitive to the microtubule stabilizing agent, paclitaxel.
111        Pretreatment of HPAECs with the actin-stabilizing agent phallacidin attenuated hyperoxia-induc
112          Corneas superfused with the f-actin stabilizing agent phallacidin had significantly lower pe
113 HER2 therapy for HER2-positive disease, bone stabilizing agents, poly(ADP-ribose) polymerase inhibito
114  grape extracts (5-20%) and concentration of stabilizing agent (polyvinyl alcohol, PVA: 1-3%).
115 liferation, and treatment with a microtubule stabilizing agent prevented them from occurring.
116                                  Addition of stabilizing agents prevents loss of the delta but not th
117 s independent of the effects of the membrane-stabilizing agent punicalagin, which inhibited both IL-1
118 otofilaments in the presence of calcium as a stabilizing agent, similar to bacterial FtsZ.
119  nm Au NPs and Ag(+) ions in the presence of stabilizing agents such as adenosine triphosphate (ATP)
120 g bound nucleotide denatures rapidly without stabilizing agents such as sucrose; and second, without
121 s review focuses on the roles and effects of stabilizing agents such as surfactants, silica, biomolec
122   To overcome resistance against microtubule stabilizing agents such as taxanes, epothilone B (EpoB)
123       Increasing soil strength with chemical stabilizing agents, such as cement, raises environmental
124                                  Microtubule-stabilizing agents, such as paclitaxel (Taxol), are effe
125  treated with clinically available mast cell-stabilizing agents suggest the potential of developing n
126 cristin, and vinblastine and the microtubule-stabilizing agent taxol also exhibited 50 to 60% inhibit
127  nocodazole was inhibited by the microtubule-stabilizing agent Taxol but not by pretreatment with a c
128                              The microtubule-stabilizing agent Taxol did not mimic this effect, sugge
129              The addition of the microtubule-stabilizing agent Taxol increased the lattice spacing of
130 colchicine and attenuated by the microtubule-stabilizing agent taxol.
131 one toxicity was occluded by the microtubule-stabilizing agent Taxol.
132  an increased sensitivity to the microtubule-stabilizing agent taxol.
133 roduct from marine sponges, is a microtubule-stabilizing agent that binds to tubulin at a site distin
134              Discodermolide is a microtubule-stabilizing agent that induces accelerated cell senescen
135            Paclitaxel (PTX) is a microtubule-stabilizing agent that is widely used in cancer chemothe
136 in the axons of neurons, is an endogenous MT-stabilizing agent that plays an important role in axonal
137           Lithium and valproic acid are mood-stabilizing agents that are often used to manage the epi
138  identification of alternative CNS-active MT-stabilizing agents that lack these potential limitations
139 es with lattice defects, we used microtubule-stabilizing agents that promote formation of polymers wi
140 e extract was used as a natural reducing and stabilizing agent to prepare bismuth nickelate nanoparti
141 lium tetrafluoroborate, BMI.BF4) was used as stabilizing agent to synthesize titanium dioxide QDs (Ti
142 s better than a current, widely used protein stabilizing agent, trehalose.
143 ted ARF is unknown, it may be related to the stabilizing agent used in the IVIG preparation.
144  modulate kinesin motility regardless of the stabilizing agent used.
145           Consistently, Taxol, a microtubule-stabilizing agent, was less effective in activating LATS
146 compare it with cromolyn sodium, a mast cell stabilizing agent with established efficacy in EIA.
147 ing macrolides known to act as a microtubule stabilizing agent with properties similar to Taxol.
148 ts with bipolar disorder who received a mood stabilizing agent with versus without an antidepressant
149 he design and synthesis of other microtubule-stabilizing agents with a similar capacity.
150 imalide represent a new class of microtubule-stabilizing agents with activities that may provide ther
151 ee of additives or containing Irgafos 168 as stabilizing agent without any sampling step.

 
Page Top